Project Details

Description

EDAP- Early diagnostics and prognostics of Alzheimer’s disease: approaches in municipality, primary health care, specialized care and industry
(LU:s Thematic Collaboration Initiative 2021– ongoing)

The long-term aim of EDAP is to improve trans- and multidisciplinary knowledge exchange and research focusing on Alzheimer’s disease.

We aim to 1) improve early diagnostics and prognostics of Alzheimer´s disease at all levels of patient management, and 2) facilitate early interventions with a meaningful impact on the disease.

Participating faculties
•Medicine
•Science
•Engineering
•Social Sciences
•School of Economics and Management.

External partners
•Region Skåne
•Lunds kommun
•Alzheimer Sverige
•NADIO (före detta Edu Med)
•BioArctic
•Cell Invent
•Eisai
•Geras Solutions
•Lilly
•Lundbeck
•neotiv
•Roche
•(Biogen was part of the application and the start-up phase)

New additional collaborators: Brain Biomarker Solutions in Gothenburg AB, Fujirebio Europé; C2N Diagnostics (US). 

Layman's description

The long-term aim of EDAP is to improve trans- and multidisciplinary knowledge exchange and research focusing on Alzheimer’s disease.
AcronymEDAP
StatusActive
Effective start/end date2021/09/01 → …

Collaborative partners

  • Lund University (lead)
  • H. Lundbeck AB (Project partner)
  • Roche AB (Project partner)
  • Eli Lilly and Company (Project partner)
  • Eisai Inc. (Project partner)
  • Cell Invent (Project partner)
  • Geras Solutions AB (Project partner)
  • BioArctic AB (Project partner)
  • Edu Med AB (Project partner)
  • neotiv (Project partner)
  • Alzheimer Sweden (Project partner)
  • Lund Municipality (Project partner)
  • Region Skåne - Primärvården, Malmö (Project partner)
  • Region Skåne (Project partner)
  • NADIO (former Edu Med AB) (Project partner)

UKÄ subject classification

  • Neurology
  • Neurosciences